EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The PAD4 inhibitor GSK484 diminishes neutrophil extracellular trap in the colon mucosa but fails to improve inflammatory biomarkers in experimental colitis

Kangzhe Xie, Jordan Hunter, Aaron Lee, Gulfam Ahmad, Paul K Witting iD, Tamara Ortiz-Cerda iD

Bioscience Reports · 27.06.2025 · 45 (06) · 375-397

DOI: 10.1042/bsr20253205 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioscience Reports, online erschienen am 11.06.2025. Verfasst von Kangzhe Xie und 5 weiteren Autor:innen. Beteiligte Einrichtung: Redox Biology Group, School of Medical Sciences, Faculty of Medicine & Health, The University of Sydney, Sydney, New South Wales 2006, Australia. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammatory bowel disease (IBD) is a gastrointestinal disorder characterised by elevated colonic neutrophil extracellular traps (NETs), which are associated with disease severity. Formation of NETs is primarily driven by peptidyl arginine deaminase IV (PAD4) and other enzymes including myeloperoxidase (MPO) and neutrophil elastase. The present study evaluated the effect of MPO and PAD4 inhibition in dextran sodium sulfate (DSS)-induced colitis. Experimental colitis was induced in male C57BL/6 mice by 2% w/v DSS in drinking water ad libitum. Treatment groups received daily oral administration of MPO inhibitor (AZD3241; 30 mg/kg) and/or intraperitoneal injection of PAD4 inhibitor (GSK484; 4 mg/kg) 4 times over 9 days. Inhibition of PAD4 significantly diminished NET density in the colonic mucosa of mice insulted with DSS, reaching levels similar to that detected in control mice. Both inhibitors offered limited improvement in disease-activity-index, a scoring system that considers the extent of weight loss, stool consistency and rectal bleeding. Histology showed that MPO and/or PAD4 inhibition did not recover DSS-induced colon histoarchitectural damage whilst Alcian blue staining demonstrated that PAD4 failed to reduce goblet cell loss. The selected dosage of PAD4 inhibition also yielded no effect on inflammatory markers and antioxidant protein levels. These data sets suggest that other mechanisms may be involved in the pathogenesis of IBD, and the appropriate dosage of GSK484 requires thorough investigation.

Schlagwörter

Stichwörter der Autor:innen

NETinflammatory bowel diseasemast cellsneutrophilsulcerative colitis

Autor:innen und Institutionen

  • Redox Biology Group, School of Medical Sciences, Faculty of Medicine & Health, The University of Sydney, Sydney, New South Wales 2006, Australia.
  • Charles Perkins Centre, School of Medical Sciences, Faculty of Medicine & Health, The University of Sydney, Sydney, New South Wales 2006, Australia.
  • Department of Biological Sciences, Purdue University, West Lafayette, Indiana, U.S.A.
  • Andrology Department, Royal Women's and Children's Pathology, Carlton, Victoria 3053, Australia.
  • Departmento de Citología e Histología Normal y patológica, Facultad de Medicina, Universidad de Sevilla, Avda. Sánchez-Pizjuán s/n Sevilla, Seville 41009, Spain.

ORCID-Profile: Paul K Witting, Tamara Ortiz-Cerda

Zitieren

APA

Xie, K., Hunter, J., Lee, A., Ahmad, G., Witting, P. K., & Ortiz-Cerda, T. (2025). The PAD4 inhibitor GSK484 diminishes neutrophil extracellular trap in the colon mucosa but fails to improve inflammatory biomarkers in experimental colitis. Bioscience Reports, 45(06), 375-397. https://doi.org/10.1042/bsr20253205

Vancouver

Xie K, Hunter J, Lee A, Ahmad G, Witting PK, Ortiz-Cerda T. The PAD4 inhibitor GSK484 diminishes neutrophil extracellular trap in the colon mucosa but fails to improve inflammatory biomarkers in experimental colitis. Bioscience Reports. 2025;45(06):375-397. doi:10.1042/bsr20253205

BibTeX
@article{Xie2025,
  author = {Xie, Kangzhe and Hunter, Jordan and Lee, Aaron and Ahmad, Gulfam and Witting, Paul K and Ortiz-Cerda, Tamara},
  title = {The PAD4 inhibitor GSK484 diminishes neutrophil extracellular trap in the colon mucosa but fails to improve inflammatory biomarkers in experimental colitis},
  journal = {Bioscience Reports},
  year = {2025},
  volume = {45},
  number = {06},
  pages = {375--397},
  doi = {10.1042/bsr20253205}
}
Kostenlos starten →